Avicanna enters new supply agreement with Knop Laboratories
by CM Staff
The purpose of the new contract is to supply a range of cannabinoid-based active pharmaceutical ingredients for the manufacturing and commercialization of proprietary cannabinoid-based pharmaceutical products in Latin America.
TORONTO — Avicanna Inc. has entered into a Master Supply Agreement with Chilean pharmaceutical company Knop Laboratories.
The company has obtained this agreement through its majority owned subsidiary Santa Marta Golden Hemp. The purpose of the new contract is to supply a range of cannabinoid-based active pharmaceutical ingredients for the manufacturing and commercialization of proprietary cannabinoid-based pharmaceutical products in Latin America.
The company stated that since 2018, Avicanna and Knop have developed a collaborative enterprise which has led to commercial imports of Avicanna´s API, including CBD and THC, which has been used in the development, production and commercialization of several cannabinoid-based products.
Avicanna also stated that this Master Supply Agreement between SMGH and Knop, the two companies are fortifying their commitments to a fruitful partnership and preparing for industrialization of Knop’s cannabinoid-based pharmaceuticals manufactured using Avicanna’s organic ingredients.
